BNTC BENITEC BIOPHARMA INC

Benitec Biopharma to Participate in Upcoming Investor Conferences in December

Benitec Biopharma to Participate in Upcoming Investor Conferences in December

HAYWARD, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming investor conferences.

Piper Sandler Annual Healthcare Conference

Date: December 4, 2024

Time of Fireside Discussion: 12:00 PM EST

Location: New York, NY

Format: Fireside Discussion & 1x1 Meetings

The Benitec presentation will also be available via live webcast .

Oppenheimer Movers in Rare Disease Summit

Date: December 12, 2024

Time of Fireside Chat: 9:50-10:40 AM EST

Location: New York, NY

Format: Panel discussion & 1x1 Meetings

Please contact your conference representative to schedule a 1x1 meeting with Benitec management.

About Benitec Biopharma Inc.

Benitec Biopharma Inc. (“Benitec” or the “Company”) is a clinical-stage biotechnology company focused on the advancement of novel genetic medicines with headquarters in Hayward, California. The proprietary “Silence and Replace” DNA-directed RNA interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). A comprehensive overview of the Company can be found on Benitec’s website at .

Investor Relations Contact:



Irina Koffler

LifeSci Advisors

Tel: (917) 734-7387



EN
26/11/2024

Underlying

BNTCBENITEC BIOPHARMA INC

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on BENITEC BIOPHARMA INC

 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Provides Operational Updates

Benitec Biopharma Provides Operational Updates -In April 2025 the Sixth and Final Subject of Cohort 1 was Safely Treated with the Low Dose of BB-301 in the Phase 1b/2a Clinical Treatment Study (NCT06185673)- -Independent Data Safety Monitoring Board Review Has Been Completed for All Six Subjects Enrolled into Cohort 1, and the Data Safety Monitoring Board Recommended Continuation of Subject Enrollment for the Phase 1b/2a Clinical Treatment Study- -Following the Positive Data Safety Monitoring Board Recommendation, Enrollment of Cohort 2 is Expected to Begin in Q4 2025- HAYWARD, Calif., ...

July 9, 2025 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Releases Third Quarter 2025 Financial Results

Benitec Biopharma Releases Third Quarter 2025 Financial Results HAYWARD, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference (“ddRNAi”) platform, today announced financial results for its third fiscal quarter ended March 31, 2025. The Company has filed its quarterly report on Form 10-Q with the U.S. Securities and Exchange Commission. “We are profoundly honored to ...

May 14, 2025 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock O...

Benitec Biopharma Inc. Announces Pricing of $30 Million Common Stock Offering HAYWARD, Calif., March 25, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (Nasdaq: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary DNA-directed RNA interference (“ddRNAi”) “Silence and Replace” platform, today announced the pricing of its underwritten offering of 1,443,000 shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and a concurrent registered direct offe...

March 25, 2025 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma Reports Positive Interim Clinical Results for Three ...

Benitec Biopharma Reports Positive Interim Clinical Results for Three Subjects Treated with BB-301 in Phase 1b/2a Study to be Presented at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 1- -Durable, Clinically Significant Improvements in Swallowing Function Achieved 12-months Post-Treatment with BB-301 for Subject 2, with Subject 2 Achieving a Clinically Normal Swallowing Profile Following the Significant Reduction in Total Dysphagic Sym...

March 19, 2025 1 EN
 PRESS RELEASE
Free
BNTC BENITEC BIOPHAR...

Benitec Biopharma to Participate in Upcoming Conferences in March

Benitec Biopharma to Participate in Upcoming Conferences in March HAYWARD, Calif., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Benitec Biopharma Inc. (NASDAQ: BNTC) (“Benitec” or the “Company”), a clinical-stage, gene therapy-focused, biotechnology company developing novel genetic medicines based on its proprietary “Silence and Replace” DNA-directed RNA interference ("ddRNAi") platform, today announced that its management team will participate in the following upcoming conferences. TD Cowen 45th Annual Health Care ConferenceDate: March 5, 2025Time of Presentation: 9:50 AM to 10:20 AM EST Format:...

February 26, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch